HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...

Health Checkups for Men After Turning 40 Reaching the age of 40 is often seen as a significant milestone in life, marking the ...

Better continence, erectile function, but data on oncologic outcomes still 2 years away ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell ...

State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

Researchers presented clinical study results on the dual-tracer PET imaging technique at the European urology conference with peer-reviewed publication forthcoming.

We present the case of a patient with an elevated prostate-specific antigen level who underwent a prostate MRI that revealed a mass between the prostate and rectum, prompting further evaluation.

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

Thank you for signing up! Did you know with an ad-lite subscription to Burnley Express, you get 70% fewer ads while viewing ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.